Jefferies Group LLC reduced its position in Shire PLC (NASDAQ:SHPG) by 61.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,117 shares of the biopharmaceutical company’s stock after selling 11,149 shares during the period. Jefferies Group LLC’s holdings in Shire were worth $1,104,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Harding Loevner LP raised its holdings in shares of Shire by 18,894.4% during the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after buying an additional 126,865,607 shares during the period. Third Point LLC purchased a new stake in shares of Shire during the 3rd quarter valued at about $183,768,000. Boston Partners raised its holdings in shares of Shire by 60.9% during the 4th quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after buying an additional 886,572 shares during the period. ING Groep NV raised its holdings in shares of Shire by 9,043.1% during the 4th quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock valued at $81,366,000 after buying an additional 518,800 shares during the period. Finally, Sterling Capital Management LLC raised its holdings in shares of Shire by 26,182.4% during the 3rd quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock valued at $72,649,000 after buying an additional 472,592 shares during the period. 19.75% of the stock is currently owned by institutional investors and hedge funds.
Shares of Shire PLC (SHPG) opened at $133.45 on Friday. Shire PLC has a twelve month low of $123.73 and a twelve month high of $192.15. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $39,976.38, a P/E ratio of 9.50, a price-to-earnings-growth ratio of 0.76 and a beta of 1.44.
The company also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be issued a $0.8937 dividend. This represents a dividend yield of 1.33%. This is an increase from Shire’s previous semiannual dividend of $0.15. The ex-dividend date is Thursday, March 8th. Shire’s payout ratio is 7.47%.
Several brokerages recently commented on SHPG. BidaskClub downgraded Shire from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Royal Bank of Canada set a $192.00 target price on Shire and gave the company a “buy” rating in a report on Monday, February 5th. Bank of America raised their target price on Shire from $236.00 to $237.00 and gave the company a “buy” rating in a report on Monday, February 5th. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a report on Tuesday, February 6th. Finally, Cantor Fitzgerald set a $222.00 price objective on Shire and gave the stock a “buy” rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $204.00.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/17/shire-plc-shpg-shares-sold-by-jefferies-group-llc.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.